NEW YORK (GenomeWeb News) – Pfizer Pharmaceuticals will use Ingenuity Systems’ bioinformatics software under a multi-year agreement, Ingenuity said today.
Under the agreement, Pfizer will integrate the Ingenuity Pathway Analysis software and related content from Ingenuity’s biological and chemical knowledgebase with other informatics solutions that Pfizer uses throughout its organization, Ingenuity said.
Ingenuity CEO Jake Leschly said that the company also has tailored “a suite of powerful capabilities” specifically for Pfizer.
The IPA software enables scientists to model and analyze biological and chemical systems, and its search functions give users access to information about genes, drugs, chemicals, protein families, cellular and disease processes, and signaling and metabolic pathways.
Financial terms of the agreement were not released.